Surgical Hemostats Market Report 2025

The surgical hemostats market size has grown strongly in recent years. It will grow from $3.68 billion in 2024 to $3.93 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. Growth during the historic period can be attributed to the rising number of surgical procedures, an increase in trauma and accident cases, a growing elderly population, greater adoption of minimally invasive surgical techniques, and a higher prevalence of chronic diseases.

The surgical hemostats market size is expected to see strong growth in the next few years. It will grow to $5.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Growth in the forecast period is expected to be driven by increasing demand for advanced wound closure products, the expansion of ambulatory surgical centers, a growing preference for biodegradable hemostats, increased use of combination hemostatic agents, and a rising incidence of lifestyle-related diseases requiring surgical intervention. Key trends during this period include technological advancements in absorbable hemostats, integration of technology in robotic surgeries, development of next-generation hemostatic formulations, incorporation with smart surgical devices, and innovations in plant-based hemostatic products.

The increasing number of trauma cases is expected to drive the growth of the surgical hemostats market in the near future. Trauma involves physical injury or emotional shock resulting from a distressing or harmful event, affecting an individual's body or mind. The rise in trauma cases is mainly due to a surge in road traffic accidents, which cause severe injuries needing immediate medical care. Surgical hemostats assist in quickly and effectively controlling bleeding during trauma cases, reducing blood loss and stabilizing patients for further treatment. For example, in 2023, the Wisconsin Department of Health Services reported that traumatic injuries caused by assault increased by 3% compared to 2022, rising from 1,544 cases to 1,584 cases. Hence, the growing occurrence of trauma cases is fueling the expansion of the surgical hemostats market.

Leading companies in the surgical hemostats market are developing advanced products using innovative materials such as absorbable oxidized regenerated cellulose (ORC) to improve bleeding control and accelerate wound healing. Absorbable oxidized regenerated cellulose is a biodegradable, plant-derived material used in surgical hemostats to stop bleeding by creating a physical barrier and encouraging clot formation at the wound site. In February 2022, Futura Surgicare Pvt. Ltd., an India-based medical device manufacturer, introduced Hemostax, an advanced absorbable ORC hemostat designed for effective intraoperative bleeding control. This product initiates hemostasis within 1.5 minutes and completes its effect in 2 to 5 minutes. It is fully absorbed within 1 to 2 weeks, eliminating the need for removal. Hemostax is user-friendly, adapts well to various surgical sites, is non-toxic, biocompatible, and possesses antibacterial properties against drug-resistant bacteria.

In May 2025, Merit Medical Systems, Inc., a US-based medical device company, acquired Biolife Delaware for $120 million. Through this acquisition, Merit Medical Systems aims to broaden its hemostasis product portfolio and reinforce its position in the global market for rapid bleeding control solutions. BioLife Delaware, L.L.C. is a US-based medical device firm specializing in the development of surgical hemostatic products.

Major players in the surgical hemostats market are Johnson And Johnson Services Inc., Medtronic plc, Becton Dickinson And Company, Stryker Corporation, Baxter International Inc., Teleflex Corporation, Integra LifeSciences Holdings Corporation., GELITA MEDICAL GmbH, B. Braun Melsungen AG, Advanced Medical Solutions Group plc, Axio Biosolutions Pvt. Ltd., Marine Polymer Technologies Inc, Biom'up USA Inc, Lotus Surgicals Pvt. Ltd, Hemostasis LLC, Biocer Entwicklungs-GmbH, CuraMedical BV, EndoClot Plus Inc, Starch Medical Inc, Tricol Biomedical Inc.

North America was the largest region in the surgical hemostats market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in surgical hemostats report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the surgical hemostats market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The surgical hemostats market consists of sales of mechanical hemostats, active hemostats, flowable hemostats, fibrin sealants, and combination hemostats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The surgical hemostats market research report is one of a series of new reports that provides surgical hemostats market statistics, including surgical hemostats industry global market size, regional shares, competitors with a surgical hemostats market share, detailed surgical hemostats market segments, market trends and opportunities, and any further data you may need to thrive in the surgical hemostats industry. The surgical hemostats market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Surgical hemostats are specialized tools or substances used during surgery to control bleeding by either clamping blood vessels or encouraging blood clot formation. Their purpose is to maintain a clear surgical area and minimize blood loss, improving visibility and safety throughout the procedure.

The primary types of surgical hemostats include topical thrombin-based hemostats, flowable hemostats, collagen-based hemostats, oxidized regenerated cellulose-based hemostats, gelatin-based hemostats, combination hemostats, and others. Topical thrombin-based hemostats are applied directly to bleeding areas to stimulate clotting by converting fibrinogen into fibrin through the action of thrombin. These come in various forms such as matrix and gel, sponges, sheets and pads, and powders. They are used in a wide range of surgeries including neurological, orthopedic, cardiovascular, gynecological, trauma, and plastic surgeries. These products are utilized by various end users including hospitals, ambulatory surgical centers, specialty clinics, and more.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.